Opening

Le capcommundes actionnaires.

An editorial and community platform for shareholders who want to understand, engage with, and dialogue constructively with the companies they own.

Read the manifesto See the companies we cover

Recent activity

II.

On screen

Video

On CapCordia

CapCordia Shareholders' Pact·June 2026

III.

Posture

« We are not an activist fund. We are not trying to impose a vision. We offer common ground — that of an informed shareholder base that understands, questions, and engages. Without aggression, without complacency. »

Read the manifesto

IV.

Approach

Our approach

Three pillars, one standard: quality.

Sourced editorial

Structured company files: thesis, catalysts, risks, calendar. Facts, not noise.

Constructive dialogue

A posture of mutual engagement with management. CapCordia is common ground, not combative activism.

Qualified community

Long-term shareholders who share a rigorous reading of the files and prepare for general meetings.

Coverage

Companies covered

Companies we cover

CapCordia is built around a small number of deeply researched files.

Key partnersTeva · AbbVie

UZEDY® sales FY25-26$215M (+52,5%)

French biotech based near Montpellier, specialised in long-acting injectable formulations through its BEPO® platform. FY 2025-26 marks the acceleration of the transition toward a stable royalty model: UZEDY® (Teva, schizophrenia) generated $215M in net sales (+52.5% YoY), and olanzapine LAI (TEV-‘749) is expected to launch in the United States in Q4 2026.

Biotechnology · Specialty drug deliveryOpen the file

HeadquartersLausanne · Reykjavík

Swiss/Icelandic ophthalmology biotech listed on Nasdaq. Following the failure of the DIAMOND-1 and DIAMOND-2 pivotal trials (OCS-01 in diabetic macular oedema, announced 29 May 2026), the thesis is being recentred on two assets: licaminlimab (OCS-02) in severe dry eye disease and privosegtor (OCS-05) in optic neuropathy neuroprotection.

Biotechnology · OphthalmologyOpen the file